Molecular Mechanisms for the Angiotensin-(1-7)-Mediated Inhibition of Metastatic Triple Negative Breast Cancer

Approximately 40,000 women in the U.S. die from breast cancer annually. An estimated 15% of all breast cancers are triple negative, wherein tumors lack estrogen receptor and progesterone receptor expression and possess unamplified human epidermal growth factor receptor 2 (HER2) levels, contributing to an absence of effective, targeted therapeutics. Furthermore, triple negative breast cancer (TNBC) is highly-aggressive with greater patient mortality rates compared with other breast cancer subtypes, necessitating development of novel treatment options.

Grantor dc:publisher

Wake Forest University

Year dc:date.issued

2014

Author dc:creator

• Arter, Alison

Language dc:language.iso

en

Handle dc:identifier.uri

http://hdl.handle.net/10339/39307

OAI identifier oai:identifier

oai:wakespace.lib.wfu.edu:10339/39307